A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

A group of mothers in Victoria say they've experienced trouble accessing the jab for a highly infectious illness that infects ...

While respiratory syncytial virus (RSV) typically causes mild symptoms in adults, the virus can be life-threatening for infants. The seasonal virus is the most common cause of lower respiratory tract ...

The ACIP is recommending the use of Enflonsia for the prevention of RSV lower respiratory tract disease in infants younger than 8 months.

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...

The WA Department of Health has sent an urgent reminder to medical staff to make sure they’re giving patients the right RSV ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50, down from 60, following ...

The recommendation for Enflonsia is indicated for respiratory syncytial virus prevention in infants under eight months of age, expanding protection options ahead of the 2025–2026 season.

It is a mistake to claim that there is not widespread research into the effectiveness of vaccines, especially those given to ...

Medical staff in Western Australia have been warned after reports of the wrong immunisations being given to patients.

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...